Bevacizumab biosimilar - Zydus Cadila

Drug Profile

Bevacizumab biosimilar - Zydus Cadila

Alternative Names: Bryxta; MAb3

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zydus Cadila
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 11 Aug 2017 Launched for Non-small cell lung cancer in India (Parenteral) before August 2017
  • 11 Aug 2017 Registered for Non-small cell lung cancer in India (Parenteral) before August 2017
  • 25 Aug 2015 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, First line therapy) in India (CTRI/2015/08/006109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top